Friday, June 20, 2025 6/20/2025

Development of a lasmiditan analogue for treatment of acute kidney injury

Award Number: R43DK103440
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2014
PERIOD OF PERFORMANCE END DATE: 07/31/2016

Group Awards By:

View Award Description

Development of a lasmiditan analogue for treatment of acute kidney injury - DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a safe and efficacious therapeutic small molecule for treatment of acute kidney injury (AKI). AKI results from diverse insults such as sepsis, ischemia-reperfusion (I/R) or nephrotoxicant exposure and nearly half of those who develop AKI do not survive. Since treatment remains largely palliative and survival rates have remained unchanged for several decades, new therapeutic approaches are desperately needed. The role of mitochondrial dysfunction in animal models of AKI has been validated, but there is no approved therapeutic that specifically targets mitochondrial biogenesis (MB) to stimulate mitochondrial function and restore renal function. We have recently published a proof-of-principle study using the ?2-adendergic receptor agonist formoterol that demonstrates stimulation of MB restores mitochondrial function and accelerates recovery from AKI in a murine model (Jesinkey et al., JASN-2013-09-0952). Lasmiditan, a 5-HT1F receptor agonist, is a novel methylpiperidinyl- benzamide that is in phase II clinical trials for treatment f migraines. It should be noted that lasmiditan has CNS-related adverse events. We discovered that lasmiditan is also a potent inducer of MB in renal proximal tubular cells. We also identified an analogue of lasmiditan (aza-lasmiditan) in which the piperidine ring is replaced with a 1,4-piperazine ring that is an equally potent inducer of MB. Aza-lasmiditan is a new chemical entity (NCE) that is not captured in the lasmiditan composition of matter patents. Aza-lasmiditan is also synthesized in 2 steps, as opposed to the 6-step lasmiditan synthesis. We hypothesize that potent aza- lasmiditan analogues that stimulate MB with limited CNS penetration can be used to treat AKI. In Aim 1 we will synthesize 30-50 aza-lasmiditan analogues that will be modified to maintain MB activity while reducing CNS exposure via changes in polarity and/or attachment of cleavable renal-targeting moieties. The analogues will be tested for receptor binding and MB activity in an in vitro primary renal cell assay. In Aim 2 structurally diverse analogues that are particularly potent and/or efficacious will initially be injected i.v. into mice to determine MB efficacy in kidney and brain, serum half-life, and CNS concentrations In Phase II, these compounds will be tested for efficacy in murine models of AKI.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = -$104,759 )
2020	2014	MITOHEALTH, INC	280 CALHOUN ST	CHARLESTON	SC	29425	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	10/1/2019	NEW	-$104,759
														Subtotal = -$104,759

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2014	MITOHEALTH, INC	280 CALHOUN ST	CHARLESTON	SC	29425	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	2/6/2017	NEW	$0
														Subtotal = $0

Issue Date FY: 2014 ( Subtotal = $232,938 )
2014	2014	MITOHEALTH INC	POST OFFICE BOX 1572	MOUNT PLEASANT	SC	29465	CHARLESTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	9/18/2014	NEW	$232,938
														Subtotal = $232,938

Grand Total All Awards = $128,179

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a lasmiditan analogue for treatment of acute kidney injury

Award Number: R43DK103440

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2014

PERIOD OF PERFORMANCE END DATE: 07/31/2016

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer